Viz.ai has secured approval from the US Food and Drug Administration (FDA) for its artificial intelligence (AI)-based algorithm to identify suspected cerebral aneurysms.
The new AI-based algorithm, dubbed Viz Aneurysm, is said to be the first of its kind population health tool designed to facilitate population screening and enhanced care management.
Viz.ai’s new algorithm helps patients to receive the appropriate follow-up care, in addition to providing significant financial benefits for hospital systems and payers.
A study at the University of Toronto assessed the accuracy of Viz Aneurysm by adopting 528 CTAs with 674 aneurysms broadly distributed across the cerebral vascular territories. It included anterior and posterior circulation.
According to the company, the data analysis revealed 94% accuracy for the algorithm.
Viz.ai chief clinical officer Jayme Strauss said: “Viz Aneurysm has the potential to significantly increase the number of aneurysms detected and clinically followed.
“The combination of detection with an ability to schedule patients for neurovascular specialist follow-up is an important advancement for aneurysm patients, helping patients obtain the necessary follow-up from this potentially deadly disease and driving improved outcomes on the population health level.”
The Viz Aneurysm module is part of the Viz intelligent care coordination platform, which is clinically validated and reimbursed by Medicare, said the company.
Viz is an advanced neurovascular and vascular AI platform that will help coordinate care across a range of clinical applications, including ischemic and haemorrhagic stroke, pulmonary embolism and aortic disease in more than 1,000 hospitals.
In February 2018, the company secured FDA approval for its Viz LVO, a computer-aided triage and notification software.
